Royalty payment

Paratek Pharmaceuticals Announces Full Year 2019 Total Revenues of $16.5 Million including NUZYRA® (omadacycline) Net Sales of $11.5 Million

Tuesday, February 25, 2020 - 9:01pm

NUZYRA generated $11.5 million in net sales in the 11 months since its February 2019 launch.

Key Points: 
  • NUZYRA generated $11.5 million in net sales in the 11 months since its February 2019 launch.
  • NUZYRA generated $5.4 million in net sales in the fourth quarter of 2019, an increase of 74% versus prior quarter, driven by increases in demand.
  • Paratek is eligible to receive $6.0 million upon regulatory approval and royalties on net sales.
  • Under the terms of the agreement, Paratek will earn high single-digit royalties on net sales.

Exelixis Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Tuesday, February 25, 2020 - 9:05pm

Exelixis earned $17.0 million in royalty revenues based upon Ipsens cabozantinib-related revenues in the fourth quarter of 2019.

Key Points: 
  • Exelixis earned $17.0 million in royalty revenues based upon Ipsens cabozantinib-related revenues in the fourth quarter of 2019.
  • Under the collaboration agreement with Ipsen, Exelixis received a $3.0 million milestone payment for the Health Canada approval, which was recognized as revenue in the fourth quarter of 2019.
  • Under the collaboration agreement with Ipsen, Exelixis received a $2.0 million milestone payment for the Health Canada approval, which was recognized as revenue in the fourth quarter of 2019.
  • Exelixis management will discuss the companys financial results for the fourth quarter and full year 2019 and provide a general business update during a conference call beginning at 5:00 p.m.

Arecor Achieves Second License Milestone Payment From Global Pharmaceutical Partner

Tuesday, February 25, 2020 - 7:00am

The first milestone was triggered in October 2017 following the signature of a license agreement between the parties.

Key Points: 
  • The first milestone was triggered in October 2017 following the signature of a license agreement between the parties.
  • In accordance with the license agreement, the partner has rights to further develop, manufacture and commercialise a novel, superior formulation of a biosimilar product, which was developed by Arecor using its proprietary Arestat platform.
  • Under the terms of the exclusive global, royalty bearing license, a second milestone payment has been duly triggered.
  • Sarah Howell, Chief Executive Officer of Arecor, said:"The achievement of this second license milestone with our valued partner is an important testament of our ability to develop differentiated formulations of existing products that meet clinical and regulatory requirements.

RedHill Biopharma Enters $115 Million Non-Dilutive Financing Agreement with HealthCare Royalty Partners

Tuesday, February 25, 2020 - 7:00am

HCR is very excited to partner with RedHill as it looks to fund its growth.

Key Points: 
  • HCR is very excited to partner with RedHill as it looks to fund its growth.
  • SVB Leerink acted as exclusive financial advisor andCravath, Swaine & Moore LLP acted as special transaction counsel to RedHill on the transaction.
  • RedHill has entered into an agreement to acquire the rights to Movantik for opioid-induced constipation.
  • HealthCare Royalty Partners(HCR) is a private investment firm that purchases royalties and uses debt-like structures to invest in commercial or near-commercial stage biopharmaceutical assets.

San Juan Basin Royalty Trust Announces Hilcorp’s 2020 Capital Plan

Monday, February 24, 2020 - 2:00pm

The San Juan Basin Royalty Trust (NYSE:SJT) (the Trust) announced today that the operator of the Trusts Subject Interests, Hilcorp Energy Company (Hilcorp), has provided the Trust with Hilcorps 2020 capital project plan for the Subject Interests (the 2020 Plan).

Key Points: 
  • The San Juan Basin Royalty Trust (NYSE:SJT) (the Trust) announced today that the operator of the Trusts Subject Interests, Hilcorp Energy Company (Hilcorp), has provided the Trust with Hilcorps 2020 capital project plan for the Subject Interests (the 2020 Plan).
  • The principal asset of the Trust is a 75% net overriding royalty interest carved out of certain oil and gas leasehold and royalty interests in properties owned by Hilcorp San Juan L.P. (the Subject Interests) located in the San Juan Basin, and more particularly in the San Juan, Rio Arriba and Sandoval counties of northwestern New Mexico.
  • Hilcorp informed the Trust that its 2020 Plan includes $0.3 million for facility projects primarily related to natural gas compression.
  • However, Hilcorp advised the Trust that the 2020 Plan is subject to revision depending upon changes in prices of natural gas.

Paratek Announces License Grant to Almirall for SEYSARA® (sarecycline) for Greater China Region

Monday, February 24, 2020 - 12:00pm

Under the terms of the agreement, Paratek will earn high single-digit royalties on net sales in the greater China region.

Key Points: 
  • Under the terms of the agreement, Paratek will earn high single-digit royalties on net sales in the greater China region.
  • As part of this agreement, Paratek and Almirall also finalized a license granting Paratek exclusive rights to develop, manufacture and commercialize sarecycline outside of the U.S.
  • Under the terms of the agreement, Paratek will share with Almirall any potential revenues of SEYSARA (sarecycline) outside of the U.S. and greater China region.
  • Paratek has a collaboration agreement withZaiLab for the development and commercialization of omadacycline in the greaterChinaregion and retains all remaining global rights.

Yamana Gold Announces the Sale of Its Royalty Portfolio for Total Consideration of $65 Million, Creating a New Royalty Company, and Unlocking Further Value by Continuing the Execution of Its Portfolio Optimization Strategy

Monday, February 24, 2020 - 2:45am

The Sale Transaction marks another step in the Companys efforts to optimize its portfolio and improve its financial flexibility.

Key Points: 
  • The Sale Transaction marks another step in the Companys efforts to optimize its portfolio and improve its financial flexibility.
  • The sales consideration is expected to advance the Companys generative exploration program and for other purposes, including contributing to the Companys dividend reserve fund.
  • The Sale Transaction also provides Yamana with a meaningful stake in a new royalty company that has a strong asset base, like-minded corporate objectives, and a growth mandate.
  • Upon closing of the Acquisitions, Guerrero intends to change its corporate name to Nomad Royalty Company Ltd. (Nomad).

Aeterna Zentaris Announces Closing of $4.5 Million Registered Direct Offering Priced At-The-Market

Friday, February 21, 2020 - 7:00pm

The gross proceeds to the Company from the offering totaled approximately $4.5 million, before deducting placement agent fees and offering expenses.

Key Points: 
  • The gross proceeds to the Company from the offering totaled approximately $4.5 million, before deducting placement agent fees and offering expenses.
  • Aeterna Zentaris intends to use the net proceeds from the offering for general corporate purposes, which includes, among other purposes, the funding of a pediatric clinical trial in the E.U.
  • Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests.
  • Macrilen is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales.

VIVUS Announces Commercial Launch of Qsymia® in the Republic of Korea Establishing New Royalty Revenue Stream

Wednesday, February 19, 2020 - 12:30pm

We are confident in Alvogens ability to make Qsymia a significant product in the South Korean market.

Key Points: 
  • We are confident in Alvogens ability to make Qsymia a significant product in the South Korean market.
  • Under the agreement, VIVUS is also eligible to receive royalties on Alvogen's net sales of Qsymia and future milestone payments contingent upon achievement of net sales goals within the covered territory.
  • Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy.
  • These risks and uncertainties could cause actual results to differ materially from those referred to in these forward-looking statements.

Fish & Richardson Wins Over $31 Million for Wasica and BlueArc in Long-Running Patent Dispute

Tuesday, February 18, 2020 - 3:40pm

The case is the latest chapter of an international patent dispute that started nearly 20 years ago between the parties.

Key Points: 
  • The case is the latest chapter of an international patent dispute that started nearly 20 years ago between the parties.
  • Wasica and BlueArc sued Schrader in the U.S. in 2013 after years of alleged infringement.
  • While many companies had licensed the technology, Schrader sold about 164 million sensors that used the technology without paying royalties.
  • When Uwatec was eventually sold, the owners kept the rights to the tire pressure monitoring technology and formed Wasica and BlueArc to hold the patent rights.